Innodem Neurosciences Signs a Strategic Partnership with Novartis Pharmaceuticals Canada Inc.
PR92121
MONTREAL, Oct. 5, 2021 /PRNewswire=KYODO JBN/ --
Innodem Neurosciences announced today that it has signed a multi-year
partnership agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to
conduct a breakthrough clinical trial to help people living with multiple
sclerosis (MS).
Innodem's AI-powered, patented, eye tracking software technology is embodied in
a mobile application that turns a tablet into a device capable of capturing and
analyzing Eye Movement Biomarkers (EMBs) and Gaze Mapping Biomarkers (GMBs) to
assist a clinician's diagnosis and monitor MS disease progression.
Digital EMB and GMB tests are non-invasive and can be completed in minutes in
the clinic's waiting room or by the patient at home. Remote self-testing is a
major advantage during a pandemic and for people living with MS residing in
rural areas who cannot easily access a neurologist.
"The financing from Novartis will fund a carefully designed cross-sectional and
longitudinal MS study that will last until 2027. As a practicing neurologist,
I'm hopeful that the study will validate just how Innodem's technology can
assist clinicians in monitoring disease progression as early as possible to
improve MS treatment and patient outcomes," said Dr. Etienne de Villers-Sidani,
cognitive neurologist, main founder and Chief Executive Officer of Innodem.
"This partnership is the result of an ongoing collaboration that was
architected over the past two years. It embodies our common goal and commitment
to improving quality of care for people living with MS globally," added Marc
Reeves, co-founder and Chief Business Officer of Innodem.
"At Novartis, we are committed to innovation and becoming the leaders in the
health tech space. After reviewing existing solutions, we selected Innodem's
proprietary eye tracking technology and believe it to be the most promising and
one that can easily scale due to its ease-of-use. We anticipate that the trial
will confirm its relevancy so that more people living with MS and treating
clinicians can have access to it in Canada and across the world," commented
Andrea Marazzi, Country Pharma Organization Head, Novartis Pharmaceuticals
Canada Inc.
Over the course of the trial, people living with MS will test twice a month and
the data will be correlated with the current gold standard Expanded Disability
Status Scale (EDSS), Brief International Cognitive Assessment for MS (BICAMS)
and Multiple Sclerosis Functional Composite (MSFC) scores to assist clinicians
in detecting subtle changes indicative of disease progression and that may not
show up using magnetic resonance imaging (MRI).
Innodem management believes that the multi-year trial will demonstrate that
novel digital EMBs and GMBs can measure these changes accurately, easily and
cost-effectively. "A clinician whose patient shows objective signs of
progressive MS may recommend a better adapted treatment which could, if
detected early, prevent this individual from developing further disability. No
practical companion diagnostic test currently exists to detect progressive MS,
and I believe EMBs and GMBs can fill that important gap," added Dr. de
Villers-Sidani.
About INNODEM NEUROSCIENCES
Founded in 2016, Innodem Neurosciences has developed patented mobile digital
biomarking technology of neurodegenerative diseases such as Multiple Sclerosis,
Alzheimer's disease, Parkinson's disease and related disorders, Frontotemporal
Dementia and related disorders and Cancer-Related Cognitive Impairment ("chemo
brain"). This novel eye-tracking and cognition testing technology is embodied
in a HIPAA/PIPEDA compliant system consisting of an intuitive tablet
application connected to a cloud-based AI infrastructure. The app is made up of
a series of tasks that are completed in minutes, where a user's eye movement is
recorded in data sets called Eye Movement Biomarkers (EMBs) and Gaze Mapping
Biomarkers (GMBs). Innodem's core team, led by cognitive neurologist & CEO Dr.
Eìtienne de Villers-Sidani, is composed of an intersectional group of
neuroscientists, software engineers, data scientists, healthcare professionals
and serial entrepreneurs. The company's mission is to provide easier ways to do
remote testing for all stages of neurodegenerative diseases and cancer-related
cognitive impairment to improve quality of care and patient outcomes, at unseen
levels of user-friendliness and cost-effectiveness for the global health
system. For further information, please consult www.innodemneurosciences.com
Contact: Valerie Gonzalo, AGO Communications, 514-923-1549, valerie@agocom.ca
SOURCE: Innodem Neurosciences
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。